Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance

KRAS mutations drive resistance to diverse targeted therapies. In this study, the authors show that the rare codons of KRAS , yielding low oncogene expression, can be overcome to drive resistance to anti-EGFR therapy in CRC through upregulation of global tra…